Aardvark says FDA lifted clinical hold on ARD-101 for Prader-Willi hyperphagia
Aardvark plans an FDA meeting in early 2027 on its ARD-101 development plan and expects to resume PWS clinical work that year, with $60.3 million in cash as of September 30, 2026.
Aardvark Therapeutics reported on November 13, 2026 that the FDA lifted the clinical hold on its IND application for ARD-101 for hyperphagia in Prader-Willi Syndrome in October 2026.1 The lifting followed an FDA-required ECG study in healthy volunteers and an in vitro cardiac sodium channel study, which found no prolongation of the QRS or QT interval at ARD-101 doses of 200 mg or 400 mg twice daily.1 The FDA agreed that Aardvark may conduct an open-label trial at 200 mg twice daily in patients with PWS.1
Following the hold's lifting, Aardvark requested a meeting with the FDA, now scheduled for the first quarter of 2027, to discuss its proposed clinical development plan, and the company expects to resume PWS clinical activities in 2027, subject to FDA alignment.1
The company also disclosed exploratory results from its terminated Phase 3 HERO trial and an open-label extension. The HERO trial enrolled 67 of a planned 90 participants before early termination, making all efficacy data exploratory, observational and inconclusive.1 Hyperphagia Questionnaire for Clinical Trials scores fell in both the ARD-101 and placebo arms, with the ARD-101 group showing numerically larger declines at Weeks 2, 4 and 8.1 The company said ARD-101 was generally well tolerated, with treatment-emergent adverse events in 52% of ARD-101 patients versus 50% on placebo.1 One serious cardiac adverse event occurred at 800 mg twice daily in a patient also taking pitolisant, which the FDA attributed to a drug-drug interaction.1
On finances, Aardvark held $60.3 million in cash, cash equivalents and short-term investments as of September 30, 2026, down from $73.9 million at the end of the second quarter.1 The company said this is expected to fund operations through 2027.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.